Post by Algaurizin

A drug 20+ years in the making is about to change how we treat ADHD. Most people have never heard of centanafadine. But if the FDA approves it this July, it could be the biggest shift in ADHD treatment in decades. Here's the wild journey behind it ━━━━━━━━━━━━━━━ Early 2000s, A small biotech called DOV Pharmaceutical makes a discovery. They identify a new class of compound, a "triple reuptake inhibitor", that blocks the reabsorption of dopamine, norepinephrine, AND serotonin simultaneously. No approved ADHD drug does all three. 2011, The compound (then called EB-1020) gets spun off into a new company: Neurovance. Human trials begin. Five Phase 1 studies. Two Phase 2 trials. Results? Efficacy approaching stimulants, but with a fraction of the abuse potential. 2017 — Otsuka Pharmaceutical sees the potential and acquires Neurovance. 2020 — Two Phase 3 adult trials. Both hit their primary endpoints. ✅ 2023 — Pediatric and adolescent trials. Positive again. ✅ November 2025 — Otsuka files an NDA with the FDA. January 2026 — FDA grants PRIORITY REVIEW. ✅ July 24, 2026 — FDA decision expected. ━━━━━━━━━━━━━━━ Why does this matter? → 15.5 million adults in the US have ADHD → Over 90% of current treatments are stimulants → Stimulants carry real risks: addiction, cardiovascular side effects, diversion → Centanafadine is non-stimulant, first-in-class, and shows stimulant-level efficacy This isn't just a new drug. It's potentially a new category. ━━━━━━━━━━━━━━━ What do you think, will non-stimulant ADHD treatments finally get the attention they deserve? Drop your thoughts below. And if you found this useful, repost to share it with someone in pharma, psychiatry, or neuroscience. #ADHD #DrugDiscovery #Neuroscience